Buscar
Regenxbio Inc
RGNXAñadir a la lista de seguimiento
13.280USD
+0.190+1.45%
Cierre 07/02, 13:00（ET）Cotizaciones retrasadas 15 min
686.54MCap. mercado
PérdidaP/E TTM
Más Datos de Regenxbio Inc Compañía
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Información de Regenxbio Inc
Símbolo de cotizaciónRGNX
Nombre de la empresaRegenxbio Inc
Fecha de salida a bolsaSep 17, 2015
Director ejecutivoSimpson (Curran M)
Número de empleados353
Tipo de seguridadOrdinary Share
Fin del año fiscalSep 17
Dirección9804 Medical Center Drive
CiudadROCKVILLE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal20850
Teléfono12405528181
Sitio Webhttps://regenxbio.com/
Símbolo de cotizaciónRGNX
Fecha de salida a bolsaSep 17, 2015
Director ejecutivoSimpson (Curran M)
Ejecutivos de Regenxbio Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Mitchell Chan
Mr. Mitchell Chan
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
127.72K
+57.74%
Mr. Craig Malzahn
Mr. Craig Malzahn
Executive Vice President - Product Development, Chief Technology Officer
Executive Vice President - Product Development, Chief Technology Officer
82.19K
+78.61%
Dr. Olivier Danos, Ph.D.
Dr. Olivier Danos, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
58.37K
-123.06%
Mr. Curran M. Simpson
Mr. Curran M. Simpson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
45.81K
-165.45%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Independent Director
Independent Director
31.87K
+30.77%
Mr. Daniel Tasse
Mr. Daniel Tasse
Lead Independent Director
Lead Independent Director
28.86K
+33.98%
Mr. George V. Migausky
Mr. George V. Migausky
Independent Director
Independent Director
28.86K
+33.98%
Mr. Kenneth T. (Ken) Mills
Mr. Kenneth T. (Ken) Mills
Chairman of the Board
Chairman of the Board
--
--
Dr. A. N. (Jerry) Karabelas, Ph.D.
Dr. A. N. (Jerry) Karabelas, Ph.D.
Independent Director
Independent Director
--
--
Mr. Allan M. Fox, J.D.
Mr. Allan M. Fox, J.D.
Director
Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Mitchell Chan
Mr. Mitchell Chan
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
127.72K
+57.74%
Mr. Craig Malzahn
Mr. Craig Malzahn
Executive Vice President - Product Development, Chief Technology Officer
Executive Vice President - Product Development, Chief Technology Officer
82.19K
+78.61%
Dr. Olivier Danos, Ph.D.
Dr. Olivier Danos, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
58.37K
-123.06%
Mr. Curran M. Simpson
Mr. Curran M. Simpson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
45.81K
-165.45%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Independent Director
Independent Director
31.87K
+30.77%
Mr. Daniel Tasse
Mr. Daniel Tasse
Lead Independent Director
Lead Independent Director
28.86K
+33.98%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Regenxbio Inc?
Los cinco principales accionistas de Regenxbio Inc son: Mr. Mitchell Chan
¿Cuántas instituciones poseen acciones de Regenxbio Inc (RGNX)?
A fecha de 2026Q1, 410 instituciones poseen acciones de Regenxbio Inc, con un valor de mercado combinado de aproximadamente 45.28M, lo que representa el 87.72% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -3475301.00.